Pharmaceutical composition for use in the treatment of hepatitis B virus infection or co-infection

摘要

Described are pharmaceutical compositions for use in the treatment of hepatitis B virus infection or co-infection in an adult human patient for once a day administration, comprising from 0.5 mg to 1.0 mg of entecavir adhered to a pharmaceutically acceptable carrier substrate.